Inari Medical to Participate in the Jefferies London Healthcare Conference
Get Alerts NARI Hot Sheet
Join SI Premium – FREE
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 10:00 AM Greenwich Mean Time / 5:00 AM Eastern Time.
A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relations” section of the company’s website at: www.inarimedical.com.
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underserved health needs. In addition to our purpose-built solutions, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous disease, including venous thromboembolism, chronic venous disease and beyond. We are just getting started. Learn more at www.inarimedical.com and connect with us on LinkedIn, X (Twitter), and Instagram.
Investor Contact:
Marissa Bych
Gilmartin Group LLC
[email protected]
Source: Inari Medical, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tax Lien Wealth Builders Named No. 3212 on the 2026 Inc. 5000 List
- Dr. Hamid Alam Announces New Scholarship for Aspiring U.S. Physicians
- Solana Cuts Block Times Toward 200ms, Is AlphaPepe the Best Crypto To Buy Now for Bigger Upside?
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share